Drug Search Results
More Filters [+]

Maribavir

Alternative Names: maribavir, shp-620, shp 620, shp620, Livtencity
Latest Update: 2024-10-11
Latest Update Note: Clinical Trial Update

Product Description

Maribavir is a benzimidazole riboside with activity against cytomegalovirus (CMV).  (Sourced from: https://www.nejm.org/doi/full/10.1056/NEJMoa1714656)

Mechanisms of Action: pUL97 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Belgium | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Norway | Poland | Portugal | Romania | Slovakia | Slovenia | Spain | Sweden | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Maribavir

Countries in Clinic: Australia, Austria, Belgium, Brazil, Canada, China, Croatia, Czech Republic, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, New Zealand, Poland, Russia, Singapore, Spain, Switzerland, Turkey, United Kingdom, United States

Active Clinical Trial Count: 14

Highest Development Phases

Phase 3: Cytomegalovirus Infections|Hematopoietic Stem Cell Transplant|Transplantation Unspecified

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TAK-620-2004

P3

Unknown Status

Hematopoietic Stem Cell Transplant|Transplantation Unspecified

2027-03-31

TAK-620-3002

P3

Not yet recruiting

Cytomegalovirus Infections

2027-02-05

82%

TAK-620-2004

P3

Recruiting

Cytomegalovirus Infections

2027-01-18

jRCT2031230753

P3

Recruiting

Transplantation Unspecified|Hematopoietic Stem Cell Transplant

2026-11-22

Recent News Events